niacinamide has been researched along with Germinoblastoma in 9 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase I trial evaluated the combination of the marine-derived cyclodepsipeptide plitidepsin (trade name Aplidin) with sorafenib or gemcitabine in advanced cancer and lymphoma patients." | 9.24 | Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. ( Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M, 2017) |
| "The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines." | 7.79 | Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. ( Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E, 2013) |
| "Sorafenib was well tolerated and had a clinical activity that warrants development of combination regimens." | 6.77 | Phase II study of sorafenib in patients with relapsed or refractory lymphoma. ( Anichini, A; Barbati, C; Carlo-Stella, C; Corradini, P; Devizzi, L; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Guidetti, A; Lanocita, R; Locatelli, SL; Malorni, W; Marchianò, A; Matteucci, P; Mortarini, R; Pierdominici, M; Tarella, C, 2012) |
| "Sorafenib cytotoxicity was assessed in vitro and growth inhibition (IC50) was calculated." | 5.36 | 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models. ( Ambrosini, V; D'Errico-Grigioni, A; Fanti, S; Fini, M; Franchi, R; Giavaresi, G; Malvi, D; Nanni, C; Quarta, C; Torricelli, P; Zinzani, PL, 2010) |
| "This phase I trial evaluated the combination of the marine-derived cyclodepsipeptide plitidepsin (trade name Aplidin) with sorafenib or gemcitabine in advanced cancer and lymphoma patients." | 5.24 | Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. ( Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M, 2017) |
| "The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines." | 3.79 | Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. ( Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E, 2013) |
| "Sorafenib was well tolerated and had a clinical activity that warrants development of combination regimens." | 2.77 | Phase II study of sorafenib in patients with relapsed or refractory lymphoma. ( Anichini, A; Barbati, C; Carlo-Stella, C; Corradini, P; Devizzi, L; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Guidetti, A; Lanocita, R; Locatelli, SL; Malorni, W; Marchianò, A; Matteucci, P; Mortarini, R; Pierdominici, M; Tarella, C, 2012) |
| " Accumulating evidences show that chemotherapeutic drugs could act as immune supportive instead of immunosuppressive agents when proper dosage is used, and combined with immunotherapy often results in better treatment outcomes than monotherapy." | 1.40 | Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment. ( Chang, YF; Chuang, HY; Hwang, JJ; Liu, RS, 2014) |
| "Sorafenib cytotoxicity was assessed in vitro and growth inhibition (IC50) was calculated." | 1.36 | 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models. ( Ambrosini, V; D'Errico-Grigioni, A; Fanti, S; Fini, M; Franchi, R; Giavaresi, G; Malvi, D; Nanni, C; Quarta, C; Torricelli, P; Zinzani, PL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlo-Stella, C | 2 |
| Locatelli, SL | 2 |
| Giacomini, A | 1 |
| Cleris, L | 1 |
| Saba, E | 1 |
| Righi, M | 1 |
| Guidetti, A | 2 |
| Gianni, AM | 2 |
| Chuang, HY | 1 |
| Chang, YF | 1 |
| Liu, RS | 1 |
| Hwang, JJ | 1 |
| Aspeslagh, S | 1 |
| Stein, M | 1 |
| Bahleda, R | 1 |
| Hollebecque, A | 1 |
| Salles, G | 1 |
| Gyan, E | 1 |
| Fudio, S | 1 |
| Extremera, S | 1 |
| Alfaro, V | 1 |
| Soto-Matos, A | 1 |
| Soria, JC | 1 |
| Ambrosini, V | 1 |
| Quarta, C | 1 |
| Zinzani, PL | 1 |
| Nanni, C | 1 |
| Fini, M | 1 |
| Torricelli, P | 1 |
| Giavaresi, G | 1 |
| D'Errico-Grigioni, A | 1 |
| Malvi, D | 1 |
| Franchi, R | 1 |
| Fanti, S | 1 |
| Malorni, W | 1 |
| Pierdominici, M | 1 |
| Barbati, C | 1 |
| Mortarini, R | 1 |
| Devizzi, L | 1 |
| Matteucci, P | 1 |
| Marchianò, A | 1 |
| Lanocita, R | 1 |
| Farina, L | 1 |
| Dodero, A | 1 |
| Tarella, C | 1 |
| Di Nicola, M | 1 |
| Corradini, P | 1 |
| Anichini, A | 1 |
| ALTENBRUNN, HJ | 1 |
| STEENBECK, L | 1 |
| EHRHARDT, E | 1 |
| SCHMAGLOWSKI, S | 1 |
| Clemetson, KJ | 1 |
| Chen, B | 1 |
| Zupkó, I | 1 |
| de Witte, PA | 1 |
| Calcutt, G | 1 |
| Ting, SM | 1 |
| Preece, AV | 1 |
2 trials available for niacinamide and Germinoblastoma
| Article | Year |
|---|---|
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Disease-Free S | 2012 |
7 other studies available for niacinamide and Germinoblastoma
| Article | Year |
|---|---|
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell | 2013 |
Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Mo | 2014 |
18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Evaluation, Preclinical; F | 2010 |
[INVESTIGATION ON THE DECREASE IN CONCENTRATION OF NAD IN LYMPHOSARCOMA ASCITES CELLS FOLLOWING X-IRRADIATION].
Topics: Ascites; Chromatography; Lymphoma; Lymphoma, Non-Hodgkin; Metabolism; NAD; Neoplasms; Neoplasms, Exp | 1965 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Anemia, Sickle Cell; Antibiotics, Antineoplastic; Antigens, CD20; Benzamides; Benzenesulfonates; CD4 | 2007 |
Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy.
Topics: Animals; Anthracenes; Blood Vessels; Dose-Response Relationship, Drug; Female; Fluorescein; Hydralaz | 2001 |
Tissue NAD levels and the response to irradiation of cytotoxic drugs.
Topics: Animals; beta-Aminoethyl Isothiourea; Cysteamine; Female; Lymphoma; Male; Mechlorethamine; Mice; NAD | 1970 |